Replies to post #485081 on Anavex Life Sciences Corp (AVXL)

[xodcode]

If neither MAA approval comes nor 3-71 results are extremely good, then...there is no NPV calc that makes sense because the stock would be sitting at ~$350m based purely on speculation that the company could run a pair of truly effective PD P3 trials.

So, according to your AVXL analysis, what is the chance of:

i) MAA non approval

ii} 3-71 results are a dud

[rx7171]

For $3 billion revenue in 2028
how many of the current 7 million European AD patients will be receiving the drug?

What will be the yearly revenue for Blarcamasine per patient?